From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine

References

• Rosenstein NE, Fischer M, Tappero JW. Meningococcal vaccines. Infect Dis Clin North Am. 2001;15:155–169.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62:1–28.
   PubMed Web of Science ®Google Scholar
• Harrison OB, Claus H, Jiang Y, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19:566–573.
   PubMed Web of Science ®Google Scholar
• Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367:397–403.
   PubMed Web of Science ®Google Scholar
• Kirsch EA, Barton RP, Kitchen L, et al. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J. 1996;15:967–978. quiz 979.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Meningococcal disease: technical and clinical information. [cited 2017 Oct 4]. Available from: http://www.cdc.gov/meningococcal/clinical-info.html
   Google Scholar
• Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr. 1981;99:540–545.
   PubMed Web of Science ®Google Scholar
• Kriz P, Wieffer H, Holl K, et al. Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century. Expert Rev Vaccines. 2011;10:1477–1486.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184–191.
   PubMed Web of Science ®Google Scholar
• Menactra® (MCV4)1. Full Prescribing Information, Sanofi Pasteur Inc., Swiftwater, PA, 2014.
   Google Scholar
• Menveo® (Meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine). Full Prescribing Information, Novartis Vaccines and Diagnostics, Inc., Sovicille, Italy, 2013.
   Google Scholar
• Nimenrix Product Monograph (Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine). Full Prescribing Information, Pfizer Canada Inc, Kirkland, Quebec, 2016.
   Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2:355–357.
   PubMed Web of Science ®Google Scholar
• Holst J, Oster P, Arnold R, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9:1241–1253.
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A. 2006;103:10834–10839.
   PubMed Web of Science ®Google Scholar
• Zlotnick GW, Jones TR, Liberator P, et al. The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease. Hum Vaccin Immunother. 2015;11:5–13.
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780–786.
   PubMedGoogle Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine. 2005;23:2222–2227.
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307–1326.
   PubMed Web of Science ®Google Scholar
• Vaccines and Related Biologic Products Advisory Committee. Approaches to licensure of meningococcal vaccines for prevention of serogroup B invasive meningococcal disease. Briefing document for the Vaccines and Related Biologic Products Advisory Committee Meeting. Apr 7, 2011. [cited 2017 Apr 10]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM248586.pdf
   Google Scholar
• European Medicines Agency. EPAR summary for the public: Trumenba. [ cited 2017 Oct 23]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004051/WC500228998.pdf
   Google Scholar
• MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1171–1176.
   PubMed Web of Science ®Google Scholar
• Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72:2088–2100.
   PubMed Web of Science ®Google Scholar
• McNeil LK, Murphy E, Zhao XJ, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine. 2009;27:3417–3421.
   PubMed Web of Science ®Google Scholar
• Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003;197:789–799.
   PubMed Web of Science ®Google Scholar
• Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28:6086–6093.
   PubMed Web of Science ®Google Scholar
• McNeil LK, Zagursky R, Shuo L, et al. The role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev. 2013;77:234–252.
   PubMed Web of Science ®Google Scholar
• Trumenba® (meningococcal group B vaccine). Full Prescribing Information, Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc, Philadelphia, PA, 2017.
   Google Scholar
• Vetter V, Baxter R, Denizer G, et al. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease. Expert Rev Vaccines. 2016;15:641–658.
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853–861.
   PubMed Web of Science ®Google Scholar
• MacLennan J, Kafatos G, Neal K, et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis. 2006;12:950–957.
   PubMed Web of Science ®Google Scholar
• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369:2196–2210.
   PubMed Web of Science ®Google Scholar
• Grogan J, Roos K. Serogroup B meningococcus outbreaks, prevalence, and the case for standard vaccination. Curr Infect Dis Rep. 2017;19:30.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years–United States, 2017. [ cited 2017 July 18]. Available from: https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
   Google Scholar
• Wong CA, Taylor JA, Wright JA, et al. Missed opportunities for adolescent vaccination, 2006-2011. J Adolesc Health. 2013;53:492–497.
   PubMed Web of Science ®Google Scholar
• Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years–United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64:784–792.
   PubMed Web of Science ®Google Scholar
• National Center for Immunization and Respiratory Diseases. General recommendations on immunization–recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1–64.
   PubMedGoogle Scholar
• Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014–United States. MMWR Morb Mortal Wkly Rep. 2014;63:620–624.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Ostergaard L, Diez-Domingo J, et al. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatric Infect Dis Soc. 2016;5:152–160.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Summary basis for regulatory action. [ cited 2017 Oct 23]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM424125.pdf
   Google Scholar
• Australian Government Department of Health TGA. Prescription medicines: Registration of new chemical entities in Australia. [ cited 2017 Oct 23]. Available from: https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia
   Google Scholar
• Product monograph: Trumenba. [ cited 2017 Oct 23]. Available from: https://pdf.hres.ca/dpd_pm/00041515.PDF
   Google Scholar
• European Medicines Agency. Bexsero EPAR summary for the public. [ cited 2017 Mar 27]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002333/WC500137857.pdf
   Google Scholar
• US Food and Drug Administration. Summary basis for regulatory action: Bexsero. [ cited 2017 Feb 2]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM434748.pdf
   Google Scholar
• Bexsero® (meningococcal group B vaccine). Full Prescribing Information, Novartis Vaccines and Diagnostics, Inc, Cambridge, MA, USA, 2015.
   Google Scholar
• O’Ryan M, Stoddard J, Toneatto D, et al. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014;74:15–30.
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Goldblatt D, et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001;69:1568–1573.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Summary basis for regulatory action - Menveo (August 1, 2013). [ cited 2017 Aug 16]. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM365527.pdf
   Google Scholar
• Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009;27(suppl 2):B112–B116.
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20:S58–S67.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J. 2009;28:86–91.
   PubMed Web of Science ®Google Scholar
• Knuf M, Romain O, Kindler K, et al. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: Results of an open, randomised, controlled study. Eur J Pediatr. 2013;172:601–612.
   PubMed Web of Science ®Google Scholar
• Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA. 1999;281:1520–1527.
   PubMed Web of Science ®Google Scholar
• Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A. 1998;95:3140–3145.
   PubMed Web of Science ®Google Scholar
• Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673–4680.
   PubMed Web of Science ®Google Scholar
• McNeil LK, Donald RGK, Gribenko A, et al. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine. MBio. 2018;9:e00036–e00018.
   PubMed Web of Science ®Google Scholar
• Marshall HS, Richmond PC, Nissen MD, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine. 2013;31:1569–1575.
   PubMed Web of Science ®Google Scholar
• PubMLST. Query fHbp sequences - Neisseria profile/sequence definitions database. [ cited 2018 Mar 8]. Available from: https://pubmlst.org/bigsdb?db=pubmlst_neisseria_seqdef&page=alleleQuery&locus=%2527fHbp&submit=1
   Google Scholar
• European Medicines Agency. Assessment report: Trumenba. [cited 2017 July 7]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004051/WC500228997.pdf
   Google Scholar
• Richmond PC, Nissen MD, Marshall HS, et al. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine. 2012;30:6163–6174.
   PubMed Web of Science ®Google Scholar
• Marshall HS, Richmond PC, Nissen MD, et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18–36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J. 2012;31:1061–1068.
   PubMed Web of Science ®Google Scholar
• Nissen MD, Marshall HS, Richmond PC, et al. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J. 2012;32:364–371.
   Web of Science ®Google Scholar
• Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12:597–607.
   PubMed Web of Science ®Google Scholar
• Sheldon E, Schwartz H, Jiang Q, et al. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother. 2012;8:888–895.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Beeslaar J, et al. Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents. J Pediatric Infect Dis Soc. 2016;5:180–187.
   PubMed Web of Science ®Google Scholar
• Senders S, Bhuyan P, Jiang Q, et al. Immunogenicity, tolerability, and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Dis J. 2016;35:548–554.
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–1943.
   PubMed Web of Science ®Google Scholar
• Muse D, Christensen S, Bhuyan P, et al. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J. 2016;35:673–682.
   PubMed Web of Science ®Google Scholar
• Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200:379–389.
   PubMed Web of Science ®Google Scholar
• Reiner DM, Bhuyan P, Eiden JJ, et al. Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers. Vaccine. 2016;34:809–813.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Lucksinger GH, Absalon J, et al. A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults. Vaccine. 2016;34:1465–1471.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Vesikari T, Absalon J, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;377:2349–2362.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O’Ryan M, Valenzuela MT, et al. Persistence of antibodies in adolescents 18–24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother. 2013;9:2304–2310.
   PubMed Web of Science ®Google Scholar
• Baxter R, Reisinger K, Block SL, et al. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents. J Pediatr. 2014;164:1409–1415 e1404.
   PubMed Web of Science ®Google Scholar
• Borja-Tabora C, Montalban C, Memish ZA, et al. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis. 2013;13:116.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365–367.
   PubMed Web of Science ®Google Scholar
• Borrow R, Miller E. Surrogates of protection. In: Frosch M, Maiden M, editors. Handbook of meningococcal disease. Weinheim: Wiley-VCH; 2006.
   Google Scholar
• Marshall HS, Richmond PC, Beeslaar J, et al. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2017;17:58–67.
   PubMed Web of Science ®Google Scholar
• Patton ME, Stephens D, Moore K, et al. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine - Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:509–513.
   PubMed Web of Science ®Google Scholar
• Taha MK, Hawkins JC, Liberator P, et al. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. Vaccine. 2017;35:1530–1537.
   PubMed Web of Science ®Google Scholar
• Lujan E, Partridge E, Giuntini S, et al. Breadth and duration of meningococcal serum bactericidal activity in healthcare workers and microbiologists immunized with the MenB-FHbp vaccine. Clin Vaccine Immunol. 2017.
   Web of Science ®Google Scholar
• Harris SL, Donald RG, Hawkins JC, et al. Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains. Pediatr Infect Dis J. 2017;36:216–223.
   PubMed Web of Science ®Google Scholar
• McNamara L Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a university — Oregon, 2015–2016. [ cited 2017 Oct 2]. Available from: http://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/VACCINESIMMUNIZATION/IMMUNIZATIONPARTNERSHIPS/COALITIONS/Documents/FluSumMCNAMARACarriageStudy.pdf
   Google Scholar
• Fiorito TM, Bornschein S, Mihalakos A, et al. Rapid response to a college outbreak of meningococcal serogroup B disease: Nation’s first widespread use of bivalent rLP2086 vaccine. J Am Coll Health. 2017;65:294–296.
   PubMed Web of Science ®Google Scholar
• Soeters HM, Dinitz-Sklar J, Kulkarni PA, et al. Serogroup B meningococcal disease vaccine recommendations at a university, New Jersey, USA, 2016. Emerg Infect Dis. 2017;23:867–869.
   PubMed Web of Science ®Google Scholar
• Rutgers University Student Health. General information: serogroup B meningococcal disease (“Meningitis B”). [ cited 2018 Mar 13]. Available from: http://health.rutgers.edu/meningitis/
   Google Scholar
• McNamara LA, Thomas JD, MacNeil J, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak-Oregon, 2015–2016. J Infect Dis. 2017;216:1130–1140.
   PubMed Web of Science ®Google Scholar
• Soeters HM, Whaley M, Alexander-Scott N, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college-Rhode Island, 2015–2016. Clin Infect Dis. 2017;64:1115–1122.
   PubMed Web of Science ®Google Scholar
• Oldfield NJ, Cayrou C, AlJannat MAK, et al. Rise in group W meningococcal carriage in university students, United Kingdom. Emerg Infect Dis. 2017;23:1009–1011.
   PubMed Web of Science ®Google Scholar
• Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15: P1.3)outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine. 1995;13:821–829.
   PubMed Web of Science ®Google Scholar
• Medini D, Stella M, Wassil J. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33:2629–2636.
   PubMed Web of Science ®Google Scholar
• Frosi G, Biolchi A, Sapio ML, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31:4968–4974.
   PubMed Web of Science ®Google Scholar
• Basta NE, Mahmoud AA, Wolfson J, et al. Immunogenicity of a meningococcal B vaccine during a university outbreak. N Engl J Med. 2016;375:220–228.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Shumate AM, Johnsen P, et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics. 2015;135:798–804.
   PubMed Web of Science ®Google Scholar
• Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11:11–17.
   PubMed Web of Science ®Google Scholar
• Harris S, Tan C, Andrew L, et al. Trumenba® elicits bactericidal antibodies against non–serogroup B meningococci. Presented at: European Society for Paediatric Infectious Diseases; 2017. May 23–27; Madrid, Spain.
   Google Scholar
• Patton ME, Stephens D, Moore K, et al. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine — Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:509–513.
   PubMed Web of Science ®Google Scholar
• Szilagyi PG, Rand CM, McLaurin J, et al. Delivering adolescent vaccinations in the medical home: a new era? Pediatrics. 2008;121(suppl 1):S15–S24.
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Aguilera Vaca DC, Abarca K, et al. Persistence of meningococcal antibodies and response to a third dose after a two-dose vaccination series with investigational MenABCWY vaccine formulations in adolescents. Pediatr Infect Dis J. 2015;34:e264–278.
   PubMed Web of Science ®Google Scholar
• Harris SL, Zhu D, Murphy E, et al. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis serogroup C disease. Hum Vaccin. 2011;7:68–74.
   PubMed Web of Science ®Google Scholar
• Jolley KA, Maiden MC. BIGSdb: scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics. 2010;11:595.
   PubMed Web of Science ®Google Scholar